Department of Clinical Medicinal Sciences, Konyang University, 121 Daehakro, Nonsan, 32992, Republic of Korea.
Evidence-Based Research Laboratory, Division of Clinical Pharmacotherapy, College of Pharmacy, Chung-Ang University, Seoul, 156-756, Republic of Korea.
Arch Pharm Res. 2020 Sep;43(9):932-960. doi: 10.1007/s12272-020-01268-5. Epub 2020 Sep 9.
Alzheimer's disease (AD) is a complex, progressive, neurodegenerative disorder. As with other common chronic diseases, multiple risk factors contribute to the onset and progression of AD. Many researchers have evaluated the epidemiologic and pathophysiological association between AD, cardiovascular diseases (CVDs), and cerebrovascular diseases (CBVDs), including commonly reported risk factors such as diabetes, hypertension, and dyslipidemia. Relevant therapies of CVDs/CBVDs for the attenuation of AD have also been empirically investigated. Considering the challenges of new drug development, in terms of cost and time, multifactorial approaches such as therapeutic repositioning of CVD/CBVD medication should be explored to delay the onset and progression of AD. Thus, in this review, we discuss our current understanding of the association between cardiovascular risk factors and AD, as revealed by clinical and non-clinical studies, as well as the therapeutic implications of CVD/CBVD medication that may attenuate AD. Furthermore, we discuss future directions by evaluating ongoing trials in the field.
阿尔茨海默病（AD）是一种复杂的、进行性的神经退行性疾病。与其他常见的慢性疾病一样，多种风险因素导致 AD 的发生和进展。许多研究人员评估了 AD、心血管疾病（CVDs）和脑血管疾病（CBVDs）之间的流行病学和病理生理学关联，包括常见的报告风险因素，如糖尿病、高血压和血脂异常。也有研究探索了针对 CVD/CBVD 的相关治疗方法对 AD 的缓解作用。考虑到新药开发在成本和时间方面的挑战，应该探索 CVD/CBVD 药物的治疗再定位等多因素方法，以延缓 AD 的发生和进展。因此，在这篇综述中，我们讨论了临床和非临床研究揭示的心血管风险因素与 AD 之间的关联，以及可能缓解 AD 的 CVD/CBVD 药物的治疗意义。此外，我们通过评估该领域正在进行的试验，探讨了未来的研究方向。
